Jennifer Specht

BIOGRAPHY

Dr. Specht is a Breast Medical Oncologist, clinical trialist and translational researcher.  Her research interests include molecular imaging with FDG PET and DCE-MRI to understand in vivo biology of locally-advanced breast cancer and use of FDG PET to assess response to therapy in bone-dominant metastatic breast cancer.  She is PI/Study Chair of ECOG-ACRIN EA1183/FEATURE trial which is evaluating performance of serial FDG PET/CT to predict progression free survival in patients with breast cancer bone metastasis.  She also conducts research into immunotherapeutic approaches for treatment of breast cancer with chimeric antigen receptor (CAR) T cell therapies.  In the context of a phase I trial of ROR1 CAR T cells for solid tumors (TNBC and NSCLC, NCT02706392 ), we’ve shown that while CAR T cells can be transferred safely and expand in vivo, anti-CAR immune responses are frequent and transferred CAR T cells show an exhausted phenotype which may limit efficacy.  She is primary investigator for a first-in-human, phase I trial of CAR T cells targeting a cleaved form of MUC1 in patients with breast cancer (NCT04020575).  In collaboration with scientists in the Fred Hutch Immunotherapy Integrated Research Center, correlative studies are evaluating CAR T cell trafficking to tumor sites, phenotype and persistence of CAR T cells, and changes in TME in clinical biopsies with goal of overcoming barriers to efficacy of CAR T cell therapy for solid tumors.

Share This Speaker
Speaker Details
  • Affiliation of the Speaker
    University of Washington, Fred Hutchinson Cancer Research Center
Target Therapy and immunotherapy for breast cancer

8th November 2020,15:00pm

Events of the Speaker
You might also love these events.
Past
November 7, 2020
The highlights for the 7th HKIOS include application of artificial intelligence in radiotherapy planning and biomarkers discovery, ultra-high dose rate (FLASH) radiotherapy and alternating electric fields (tumour treating fields or TTF). Many oncologists are not familiar with these brand-new modalities, which are being slowly incorporated into our clinical practice. Due to Covid-19 pandemic, we shall conduct our symposium virtually. We thank our local and overseas speakers for their stern support and contribution again.
Past
October 26, 2019
The 6th Hong Kong International Oncology Symposium (6th HKIOS) was conducted in Sheraton Hong Kong Hotel & Towers on 26th and 27th October. The event was joined by renowned speakers with a higher international representation, reflecting our initiatives in fostering international medical collaborations. Some emerging topics such as artificial intelligence, immunotherapy and radiotherapy were discussed in the symposium.